Consolidated operational revenue for Q2 FY26 was INR 418.3 Cr, representing an 8.7% YoY decline from INR 458 Cr. Segmentally, Xanthine Derivatives performed better than the previou...

Revenue from operations grew 8% YoY to INR 264.58 Cr in FY25 from INR 245.50 Cr in FY24. Microcrystalline Cellulose (MCC) remains the core segment contributing approximately 85% of...

In Q2 FY26, the Human Nutrition segment grew 22% YoY to INR 1,212 million, while Animal Nutrition grew 6% YoY to INR 193 million. The Specialized Manufacturing segment showed the h...

Domestic branded formulations grew 5.3% YoY to INR 122 Cr in Q2 FY26. International branded formulations declined 14.3% YoY to INR 22 Cr. API revenue declined 25.4% YoY to INR 44 C...

The company operates in a single pharmaceutical segment. Total revenue from operations for FY25 was INR 345.76 Cr, representing a decline of 4.61% compared to INR 362.46 Cr in FY24...

Consolidated revenue grew 7% YoY to INR 6,672 Cr in FY25. For H1 FY26, revenue increased 13% YoY to INR 3,621 Cr. The India Branded Business grew 5% YoY in Q2 FY26 to INR 639 Cr. I...

Overall revenue grew 16% YoY to INR 588 Cr in Q2 FY26. Non-GPL business grew 39.7% YoY to INR 444.3 Cr, while the GPL (Glenmark Pharma) segment declined 23.9% YoY to INR 143.7 Cr d...

Total revenue grew 2.3% YoY to INR 12,964.5 Cr in FY25. Domestic formulation sales grew 7% YoY in FY25, while US sales de-grew 15% in H1FY25 due to price erosion and supply chain i...

Consolidated revenue grew 6.3% YoY to INR 8,286 Cr in Q2 FY26. US Formulations grew 2% QoQ to USD 417 million (INR 3,634 Cr). Europe Formulations grew 17.8% YoY to INR 2,480 Cr. Gr...

Not disclosed in available documents. However, the company achieved a significant financial turnaround with a profit of INR 39.50 Cr in FY25 compared to a loss of INR 83.80 Cr in F...

The Formulations segment grew 30.10% YoY in Q3FY23 to INR 33.64 Cr, while the API segment contributed 50% of total revenue in FY23. Domestic formulations saw robust growth of 42.74...

Consolidated revenue for Q2 FY26 was INR 56.17 Cr, representing a 27.4% YoY decline from INR 77.38 Cr. The pharmaceutical product mix is dominated by Tablets at 42%, followed by Ca...

Consolidated revenue grew 10.6% YoY to INR 16,319 Cr in FY2025. The Biosimilars segment (Biocon Biologics) grew 14.2% YoY (INR 9,465 Cr), driven by US demand and the Viatris integr...

In H1 FY26, Pharma Intermediates and API (PI-API) grew 113.1% YoY to INR 255.4 Cr, while High-intensity Sweeteners grew 3.4% to INR 68.9 Cr. Contrast Media Intermediates remained f...

The company operates in two segments: Manufacturing and Trading. For the half-year ended September 30, 2025, Manufacturing revenue reached INR 4,652.08 Lakhs, representing approxim...

Consolidated revenue grew 6.8% YoY to INR 27,547.62 Cr in FY25. The One Africa segment (South Africa, Sub-Saharan, North Africa) delivered a 14% revenue growth reaching INR 3,827 C...

Revenue for Q2 FY26 was INR 247 Cr, representing a 20% YoY decline but a 21% QoQ growth. H1 FY26 revenue stood at INR 451 Cr. While specific percentage splits for APIs vs. Injectab...

In H1 FY26, the CDMO segment revenue was INR 1,120.64 Cr, representing a slight degrowth of 1.1% YoY, while the Marketable Molecules (MM) segment grew significantly by 33.7% YoY to...

Global Generics (GG) revenue grew 17% in FY2025 to INR 32,553.5 Cr, while PSAI (Pharmaceutical Services and Active Ingredients) margins were 27.1%. In Q2 FY2026, total revenue reac...

Total revenue grew 18.6% YoY to INR 7,896 Cr in FY25. Domestic revenue grew 16.4% YoY to INR 3,660 Cr, while International revenue rose 20.5% YoY to INR 4,236 Cr. In Q2 FY26, total...

In H1 FY24, Domestic business grew 6% YoY to INR 836 Cr, Export Formulations grew 31% YoY to INR 144 Cr, and API business grew 14% YoY to INR 41 Cr. However, by H1 FY26, overall re...

India formulations grew 32% in FY25 (total revenue INR 13,321 Cr). The US market contracted by 2.5% in FY25. In Q2 FY26, India formulation sales were INR 165 Cr, an 87% decline fro...

In Q2 FY26, Finished Dosages (FD) grew 29% YoY to INR 965.7 Cr (74% of revenue). Pharmaceutical Formulation Intermediates (PFI) grew 76% YoY to INR 133.1 Cr (10% share). Active Pha...

Infertility division is a key growth driver; Critical Care and Sparsh divisions grew 8-10% in volume, though value growth was limited to 4-6% due to API price erosion. CMO business...

In Q2 FY26, total revenue from operations reached INR 567.5 Cr, reflecting a 7.9% YoY growth. Historically, in FY24, the Pharma segment remained stable with a marginal 0.3% increas...

Consolidated revenue for FY25 was INR 549.65 Cr, representing a 55.2% decrease from INR 1,227.32 Cr in FY24. Standalone turnover dropped 67.1% from INR 1,672.57 Cr to INR 549.65 Cr...

Domestic Formulations revenue was INR 2,261 Mn in Q2 FY26, a decline of 3.6% YoY. International Formulations grew 21.5% YoY to INR 1,533 Mn. API revenue surged 43% YoY to INR 431 M...

The CDMO business grew 15% YoY in Q2 FY26 (INR 265.7 Cr) and 12% in H1 FY26 (INR 515.2 Cr). The Branded Generics business grew 31% YoY in Q2 FY26 (INR 114.6 Cr) and 43% in H1 FY26 ...

Formulation business for Q2 FY26 was INR 493 Cr, representing a decline of approximately 9% YoY. API business in Q2 FY26 delivered growth reaching INR 408 Cr. The chronic segment s...

Overall revenue grew 8% YoY to INR 1,085 Cr in Q2 FY26. Domestic formulations grew 9% to INR 644 Cr. The CDMO segment reported robust growth of 20% to INR 113 Cr, while Internation...

Total revenue for H1 FY26 reached INR 150.1 Cr, a 10.2% YoY increase. Q2 FY26 revenue was INR 74.5 Cr, a marginal 0.3% YoY decline due to GST 2.0 transition adjustments. Key segmen...

Revenue for HY FY26 was INR 253.13 Cr. The API segment contributes approximately 50-55% of total revenue, while the Formulations segment accounts for the remaining 45-50%. FY25 tot...

Total income from operations grew 36.53% YoY from INR 104.34 Cr in FY24 to INR 142.45 Cr in FY25. Segment-specific growth percentages are not disclosed in the available documents.

Consolidated Gross Income grew 10.17% to INR 5,554 Cr in FY25 from INR 5,041 Cr in FY24. The CDMO segment is expected to scale up significantly in FY26 to drive future growth, foll...

Formulations segment accounted for 92.6% of consolidated revenues in 9M FY2024, while the API segment contributed 6.0%. The API business grew 3% YoY to INR 1,177.2 Cr in FY2025. Co...

Consolidated revenue from operations grew 24.5% YoY to INR 138.50 Cr in FY25. However, Q2 FY26 revenue of INR 36.66 Cr showed a decline of 10.9% compared to INR 41.16 Cr in Q2 FY25...

Total revenue from operations decreased by 13.66% YoY, falling from INR 36,859.47 Lakhs in FY 2023-24 to INR 31,823.02 Lakhs in FY 2024-25. For the half-year ended September 30, 20...

Domestic Business grew 14.5% YoY to INR 3,184 Cr (86.1% of revenue), while Exports surged 82.6% YoY to INR 513 Cr (13.9% of revenue) due to BSV consolidation. The Consumer Healthca...

The company operates as a single operating segment (pharmaceutical formulations). Total revenue grew by 6.2% from INR 145 crore in FY2023-24 to INR 154 crore in FY2024-25. Revenue ...

Revenue from operations for the Aerospace and Defence segment was INR 0 for H1 FY26, as the company is in a strategic transition phase. However, Other Income grew to INR 185.32 Cr,...

Total revenue grew by 16.86% YoY, reaching INR 82.64 Cr in FY 2024-25 compared to INR 70.72 Cr in FY 2023-24, driven by expansion in the pharmaceutical distribution network.

The company reported a marginal Total Operating Income (TOI) growth of 1.10% to INR 1,554.54 Cr in FY2025. Segment performance was mixed: Generics grew by 50% to INR 128.46 Cr, Ins...

Total consolidated revenue grew 15.9% YoY to INR 4,784 Cr in FY25 from INR 4,126.9 Cr in FY24. The Pharmaceutical segment remains the primary driver, while the Crop Health Sciences...

API business split: 60% Domestic, 40% Exports. FDF business split: 28% Domestic, 72% Exports. Overall revenue remained stable at INR 1,673 Cr in FY25 compared to INR 1,684.09 Cr in...

Total revenue and segment-specific growth are not disclosed in the available documents; however, the company reported total related party transactions of INR 5.78 Cr for H1 FY26, i...

The company operates in a single segment: Manufacturing of Pharmaceutical Products. Standalone revenue grew 15.26% YoY from INR 5,374.88 Lakhs in FY24 to INR 6,195.14 Lakhs in FY25...

The company achieved a 23% YoY growth in Total Operating Income (TOI) in FY24 and approximately 12% in FY25. However, Q2 FY26 sales stood at INR 194 crore, representing a 13% YoY d...

Not disclosed in available documents.

Consolidated revenue grew 15% YoY to INR 624.8 Cr in FY21. The Vaccine segment grew 62% YoY to INR 227.8 Cr, while the Pharmaceutical segment declined 2% YoY to INR 397.0 Cr. In H1...

Total Operating Income (TOI) grew 14% YoY to INR 8,201.56 Cr in FY24. In FY25, the CDMO segment grew 15% YoY, driven by a 54% contribution from innovation-driven projects. The Pira...

Domestic Formulations grew 10.1% YoY to INR 425.00 Cr in FY25. Overall revenue showed a 5-year CAGR of ~12% ending FY24, with 13% growth in FY24 and 12% in 9M FY25. Q2 FY26 revenue...

Consolidated revenue grew 46.8% YoY to INR 400.2 Cr in H1-FY26. The B2C segment witnessed strong momentum, increasing its revenue share from 4% to 13% YoY, while B2B accounts for t...

No documents found

Consolidated revenue grew 16% YoY in FY25 to INR 177.58 Cr, with the oncology segment being the primary driver, showing an 80% increase in revenue. In H1 FY26, revenue reached INR ...

In Q2 FY26, the Formulations segment grew 18.6% YoY to INR 3,364 million, while the API segment grew 7.3% YoY to INR 830 million. For H1 FY26, Formulations revenue was INR 6,747 mi...

In Q2 FY26, the MCC segment contributed INR 66.4 Cr (60% of revenue, down from 81% YoY), the API segment recorded INR 18.41 Cr (17% of revenue, up from 7% YoY), and O&M services co...

The company operates as a pure-play API business. Total income was INR 1,294.29 Cr in FY24, a marginal decline of 0.2% YoY from INR 1,466.36 Cr in FY23. Q2 FY26 revenue was INR 314...

The company operates four segments: Non-Beta-Lactam, Beta-Lactam (6 crore bottle capacity), Molecule R&D, and Nutraceuticals. Subsidiary revenue (Nutraceuticals/R&D) reached INR 12...

Overall revenue grew 4.6% YoY in Q2 FY26 to INR 12,208m. US market grew 2% YoY to $73m. Growth Markets (Africa, LATAM, MENA, APAC) saw revenue of INR 1,468m ($17m) in Q2 FY26, with...

Consolidated revenue grew 10% YoY in FY24 to INR 48,560 Cr and 8.6% YoY in Q2 FY26 to INR 14,405.2 Cr. Domestic formulations, the largest segment, contributed 33% of revenue in H1 ...

Total income from operations for the half-year ended September 30, 2025, reached INR 3,341.76 lakhs, representing a 13.34% growth compared to INR 2,948.39 lakhs in the same period ...

The company reported revenue from operations of INR 200 crores for Q2 FY '26, representing a 20% year-on-year growth compared to INR 166 crores in Q2 FY '25. Sequentially, revenue ...

No documents found

The company operates in a single segment, Pharmaceuticals, which grew 6.22% in FY25 to INR 405.51 Cr from INR 381.76 Cr in FY24. However, Q2 FY26 revenue of INR 77.99 Cr represents...

Consolidated revenue grew 18.3% YoY to INR 2,110.97 Cr in FY2025. On a standalone basis, Formulations revenue grew 22.2% to INR 1,527.63 Cr, while APIs & Intermediates grew 13.3% t...

Consolidated revenue for the half-year ended September 30, 2025, grew by 130.47% YoY to INR 9,302.52 Lakhs from INR 4,036.33 Lakhs, primarily driven by the Paracetamol API segment.

Total revenue from operations fell 50.2% YoY from INR 150.59 Cr in FY24 to INR 74.99 Cr in FY25. Segment-specific growth percentages were not disclosed, but the company primarily o...

The company operates in a single primary segment: Manufacturing and Trading of Pharmaceutical, Nutraceutical, Herbal, and Ayurvedic Commodities. While total consolidated revenue is...

API revenue grew 8.2% YoY to INR 277 Cr in H1 FY26, while Formulations revenue grew 17.6% YoY to INR 40 Cr in H1 FY26. Total revenue for H1 FY26 was INR 323.2 Cr, up 10.57% YoY fro...

The Domestic Business grew by 11% YoY, while the Rest of the World (ROW) business recorded a 12% growth. UK operations also reflected a healthy 12% growth, whereas EU operations re...

Total operating income for Q2 FY26 was INR 887 million, a 23.6% sequential increase. The Pharmaceutical segment contributed 83% of revenue (INR 732 million), growing 30.7% QoQ. The...

Consolidated revenue grew 62% YoY in FY25 to INR 29,298 lakhs. The Davaindia vertical grew 80% YoY to INR 18,621 lakhs (64% of total), Domestic Sales grew 11% YoY to INR 6,342 lakh...

Consolidated revenue grew 19% YoY in FY25 to INR 23,242 Cr. India Formulations achieved a 9.9% CAGR (FY23-25). US growth was driven by volume expansion in the base business and new...